Less Ads, More Data, More Tools Register for FREE

Pin to quick picksArgentex Group. Regulatory News (AGFX)

  • This share is currently suspended. It was suspended at a price of 2.45
  • There is currently no data for AGFX

Trading Statement

12 Oct 2020 07:00

RNS Number : 6887B
Argentex Group PLC
12 October 2020
 

 

 

12 October 2020

 

Argentex Group PLC

 

Trading Update

Argentex Group PLC, ("Argentex", "the Group", "the Company"), the provider of bespoke foreign exchange services to institutions, corporates and high net worth individuals, today issues a trading update for the first half of the financial year ending 30 September 2020.

Argentex LLP, the Group's FCA regulated trading subsidiary, expects to report revenues for the six-month period to 30 September 2020 of £11.8 million. The 14.7% decrease in revenue vs the six months ending 30 September 2019 (£13.8 million) was primarily driven by a reduction in client activity, as the continued macro-economic uncertainty and the effects of the COVID-19 pandemic led to some clients deferring their trading activity.

This deferral of trading activity is expected to result in stronger trading volumes in the second half of the financial year. The underlying business performed well during the period as the Group added a significant number of new customers as it continued to focus on increasing the quality and diversification of its client book, while also turning down trades that exceeded the Group's risk appetite in order to maintain the integrity of its exposure profile.

The Group has delivered an increase in the rate of new client acquisition of 87% compared to the same period last year and further progressed its long-term growth strategy when it opened its new London headquarters in September, delivering on its commitments of investing in new talent across the business, including a 62% increase in sales staff.

The strong momentum in customer growth during the first half of the financial year along with the expected uptick in trading from the existing client base gives the Directors confidence that the results for the second half, traditionally the slightly stronger half, will deliver a material improvement on the first half results.

Harry Adams, Co-CEO commented: "As the long-term impact of the COVID pandemic on global markets continues to be laid bare, it has never been more important to stand by our clients and ensure their growing FX trading needs are met. Despite frustrations over the drop in trading activity throughout the period I'm proud of how our people have adapted and delivered for our clients. Whilst clients delaying their trading activity has impacted our revenues, each of them has a commercial need to remove FX risk, so we expect a significant backlog of client volumes to be realised, the timing of which will likely depend on market and geopolitical events."

Carl Jani, Co-CEO said "The strong underlying performance of the business - notably the marked elevation of new client acquisition - is testament to our focused, long-term approach. In the face of a surge of client interest, we have focused on the quality of revenue over trading volume, remaining true to our strict risk management processes. Due to strong business fundamentals we have confidence in our ability to weather the uncertain environment, supported by a new office, a growing and increasingly talented workforce and a business model with proven resilience."

Argentex will be reporting its interim results for the six months ended 30 September 2020 on 20 November 2020.

For further information please contact:

 

Argentex Group PLC

Carl Jani, Harry Adams - Co-CEOs

(Via FTI Consulting)

 

FTI Consulting (Financial PR)

Ed Berry / Shiv Talwar / Ambrose Fullalove

Telephone: 07703 330 199

argentex@fticonsulting.com

 

Numis Securities Limited (Nominated Adviser and Broker)

Stephen Westgate, Charlie Farquhar, Laura White, Hugo RubinsteinTelephone: +44 (0) 20 7260 1000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTZKLFBBBLXFBX
Date   Source Headline
26th Feb 20212:58 pmRNSDirector/PDMR Shareholding
17th Feb 20213:12 pmRNSHolding(s) in Company
9th Feb 20212:34 pmRNSHolding(s) in Company
20th Jan 20217:00 amRNSTrading update and Board changes
20th Nov 20207:00 amRNSInterim Results
19th Nov 20204:53 pmRNSHolding(s) in Company
4th Nov 20207:00 amRNSNotice of interim results
12th Oct 20207:00 amRNSDirector Declaration
12th Oct 20207:00 amRNSTrading Statement
6th Oct 20204:40 pmRNSSecond Price Monitoring Extn
6th Oct 20204:35 pmRNSPrice Monitoring Extension
30th Sep 20204:40 pmRNSSecond Price Monitoring Extn
30th Sep 20204:35 pmRNSPrice Monitoring Extension
21st Sep 20205:50 pmRNSChange of Registered Office
11th Sep 20202:18 pmRNSAGM Statement
7th Sep 20204:36 pmRNSPrice Monitoring Extension
10th Aug 20207:17 amRNSAnnual Report and Notice of Annual General Meeting
3rd Aug 20207:00 amRNSFull year results for period ending 31 March 2020
29th Jul 20204:35 pmRNSPrice Monitoring Extension
9th Jul 20207:00 amRNSNotice of Full Year Results
8th Jul 20205:24 pmRNSHolding(s) in Company
29th Jun 20209:11 amRNSHolding(s) in Company
27th May 20207:00 amRNSArgentex Group announces new headquarters
26th May 20204:40 pmRNSSecond Price Monitoring Extn
26th May 20204:35 pmRNSPrice Monitoring Extension
8th Apr 20207:00 amRNSDirector/PDMR Shareholding
1st Apr 20205:40 pmRNSHolding(s) in Company
1st Apr 20207:00 amRNSTrading Update
27th Mar 20204:41 pmRNSSecond Price Monitoring Extn
27th Mar 20204:36 pmRNSPrice Monitoring Extension
25th Mar 20204:00 pmRNSDirector/PDMR Shareholding
18th Mar 202011:46 amRNSDirector/PDMR Shareholding
17th Mar 20204:43 pmRNSSecond Price Monitoring Extn
17th Mar 20204:38 pmRNSPrice Monitoring Extension
13th Mar 20204:41 pmRNSDirector/PDMR Shareholding
11th Mar 20204:41 pmRNSHolding(s) in Company
11th Mar 20204:41 pmRNSSecond Price Monitoring Extn
11th Mar 20204:35 pmRNSPrice Monitoring Extension
9th Mar 20204:41 pmRNSSecond Price Monitoring Extn
9th Mar 20204:37 pmRNSPrice Monitoring Extension
27th Feb 202012:07 pmRNSSecond Price Monitoring Extn
27th Feb 202012:02 pmRNSPrice Monitoring Extension
26th Feb 202012:08 pmRNSSecond Price Monitoring Extn
26th Feb 202012:02 pmRNSPrice Monitoring Extension
24th Feb 20204:40 pmRNSSecond Price Monitoring Extn
24th Feb 20204:35 pmRNSPrice Monitoring Extension
20th Nov 20197:00 amRNSInterim Results Statement
7th Oct 20197:00 amRNSTrading Update
5th Aug 20197:00 amRNSAppointment of Non-Executive Director

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.